The response to chemotherapy is associated with tumor angiogenesis, and miR-484 has a potential to improve chemosensitivity through the modulation of tumor angiogenesis, by directly targeting VEGFB and KDR (formerly called VEGFR2). The gene discussed is KDR; the disease is neoplasm.